DBV Technologies to Unveil Additional VITESSE Phase 3 Data on Peanut Patch at AAAAI 2026
Event summary
- DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch in children aged 4-7 years at the AAAAI 2026 Annual Meeting.
- The presentation, titled 'VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age,' is scheduled for February 28, 2026.
- DBV will also host a product theater discussing the future of epicutaneous immunotherapy (EPIT) in pediatric food allergy treatment.
- The event will feature renowned allergists including David Fleischer, MD, Hugh Sampson, MD, Katherine Anagnostou, MD, MSc, PhD, and S. Shahzad Mustafa, MD.
The big picture
DBV Technologies' presentation at the AAAAI 2026 Annual Meeting underscores the growing interest in epicutaneous immunotherapy as a non-invasive treatment for food allergies. The focus on pediatric patients highlights the unmet medical need in this demographic and the potential for DBV's VIASKIN Peanut Patch to become a key player in allergy management. The strategic discussions around early intervention and immune system re-education position DBV at the forefront of innovative allergy treatments.
What we're watching
- Regulatory Pathway
- How the additional VITESSE Phase 3 data will influence the regulatory approval process for the VIASKIN Peanut Patch.
- Market Positioning
- Whether DBV Technologies can leverage the AAAAI presentation to strengthen its position in the pediatric food allergy treatment landscape.
- Clinical Adoption
- The pace at which allergists and pediatricians will adopt EPIT as a standard treatment option for peanut allergies.
Related topics